Spinal Fusion for Degenerative Disease

Spinal fusion for degenerative lumbar disease expanded dramatically through the 1990s and 2000s, driven by device innovation and the assumption that stabilizing painful segments would reliably reduce symptoms. Wide variation in fusion rates across geographic regions and institutions suggested that indications were not well-defined. Early Swedish RCTs by Fritzell and colleagues (2001) comparing fusion to nonsurgical care for chronic low back pain showed modest superiority for fusion, but raised questions about whether structured rehabilitation might produce comparable outcomes. These initial signals suggested the need for more rigorous evaluation of fusion indications.

The Spine Patient Outcomes Research Trial (SPORT) was a landmark multicenter study comparing surgical versus nonoperative treatment for lumbar degenerative conditions. Published in a series of papers from 2006-2008, SPORT examined three conditions: lumbar disc herniation, spinal stenosis, and degenerative spondylolisthesis. The as-treated analyses showed significant surgical benefits for all three conditions, with the greatest benefit in spondylolisthesis with stenosis where decompression plus fusion was clearly superior. However, the intention-to-treat analysis was complicated by high crossover rates (>40%), reflecting the real-world difficulty of maintaining randomization when patients have strong treatment preferences. Separately, the Brox trial from Norway (2003, 2006) found that structured cognitive-behavioral rehabilitation achieved outcomes comparable to fusion for chronic low back pain, challenging the role of fusion in non-specific back pain.

Subsequent trials refined the indications for fusion in specific clinical scenarios. The Swedish Spinal Stenosis Study demonstrated that adding fusion to decompression for stenosis without spondylolisthesis provided no additional benefit and increased operative morbidity. The rise of minimally invasive techniques (MIS-TLIF, lateral interbody fusion) aimed to reduce the surgical morbidity of fusion while maintaining clinical benefits. Total disc replacement emerged as an alternative to fusion for single-level degenerative disc disease, with FDA trials showing non-inferiority to fusion at 2 and 5 years. Long-term SPORT follow-up at 8 years showed sustained surgical benefit for stenosis and spondylolisthesis, providing reassurance about the durability of outcomes in well-selected patients.

The North American Spine Society (NASS) and AO Spine guidelines now provide nuanced recommendations for fusion based on specific pathology. Fusion is recommended as an adjunct to decompression for degenerative spondylolisthesis with stenosis, but is not routinely recommended for stenosis alone without instability. For chronic low back pain with disc degeneration, guidelines suggest fusion only after failure of comprehensive nonsurgical management and careful patient selection. NICE guidelines in the UK have been more restrictive, recommending against fusion for non-specific low back pain in most circumstances.

The field has moved toward more selective fusion indications, with strong evidence supporting fusion for spondylolisthesis with stenosis and more cautious application for non-specific back pain. Value-based spine care initiatives emphasize appropriate patient selection, shared decision-making, and outcomes measurement. Minimally invasive approaches continue to gain market share, though evidence of superiority over open techniques remains limited. Artificial disc replacement has carved out a niche for single-level disease in younger patients. Ongoing research includes biologics for fusion enhancement, motion preservation strategies, and the use of patient-reported outcomes and predictive analytics to improve surgical selection and outcomes.